Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

ABSTRACT: The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies with anti-PD-1/PD-L1 blockers as a backbone. As more and more drugs with translational potential are identified, the number of clinical trials evaluating combinations has increased considerably and the demand to prioritize combinations having potential for success over the ones that are unlikely to be successful is rising. This review aims to address the unmet need to prioritize cancer immunotherapy combinations through comprehensive search of potential drugs and ranking them based on their mechanism of action, clinical efficacy and safety. As lung cancer

SUBMITTER: Lemaire V 

PROVIDER: S-EPMC8485537 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature